Literature DB >> 10221533

Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response.

G V Quinnan1, P F Zhang, D W Fu, M Dong, H J Alter.   

Abstract

We have studied envelope protein from a donor with nonprogressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus NA. DNA was extracted from lymphocytes, which had been collected approximately 6 and 12 months prior to the time of collection of the cross-reactive serum, and env genes were synthesized, cloned, expressed on pseudoviruses, and phenotyped in NA assays. Two clones from each time point had identical V3 region nucleotide sequences, utilized CCR5 but not CXCR4 for cell entry, and had similar reactivities with reference sera. Analysis of the full nucleotide sequence of one clone (R2) demonstrated it to be subtype B and have normal predicted glycosylation. R2 pseudovirus was compared with others expressing env genes of various clades for neutralization by sera from U.S. donors (presumed or known subtype B infections), and from individuals infected with subtypes A, C, D, E, and F viruses. Neutralization by the U.S. sera of R2 and other clade B pseudoviruses was low to moderate, although R2 was uniquely neutralized by all. R2 was neutralized by 3/3, 3/3, 2/5, 5/8, and 3/4 clade A, C, D, E, and F sera, respectively. R2 and a clade E pseudovirus were neutralized by largely complementary groups of sera, potentially defining two antigenic subgroups of HIV-1. The results suggest that the epitope(s) that induced the cross-clade reactive NA in donor 2 may be expressed on the R2 envelope.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221533     DOI: 10.1089/088922299311088

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  30 in total

1.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Assessment of immunologically relevant dynamic tertiary structural features of the HIV-1 V3 loop crown R2 sequence by ab initio folding.

Authors:  David Almond; Timothy Cardozo
Journal:  J Vis Exp       Date:  2010-09-15       Impact factor: 1.355

3.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.

Authors:  M Gordon Joyce; Masaru Kanekiyo; Ling Xu; Christian Biertümpfel; Jeffrey C Boyington; Stephanie Moquin; Wei Shi; Xueling Wu; Yongping Yang; Zhi-Yong Yang; Baoshan Zhang; Anqi Zheng; Tongqing Zhou; Jiang Zhu; John R Mascola; Peter D Kwong; Gary J Nabel
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

6.  Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Authors:  Gabriel N Defang; Dimple Khetawat; Christopher C Broder; Gerald V Quinnan
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

7.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.

Authors:  Weizao Chen; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

10.  Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Authors:  Tessa Dieltjens; Leo Heyndrickx; Betty Willems; Elin Gray; Lies Van Nieuwenhove; Katrijn Grupping; Guido Vanham; Wouter Janssens
Journal:  Retrovirology       Date:  2009-12-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.